Literature DB >> 10934144

Overexpression of clusterin in human breast carcinoma.

M Redondo1, E Villar, J Torres-Muñoz, T Tellez, M Morell, C K Petito.   

Abstract

Clusterin has been implicated in numerous processes including active cell death, immune regulation, cell adhesion and morphological transformation. The purpose of this study was to examine clusterin expression in a large series of breast carcinomas by immunohistochemistry and in situ hybridization. The study included 40 samples of non-neoplastic glandular epithelia, 42 benign lesions, 15 atypical intraductal hyperplasias, 35 carcinomas in situ, 114 invasive carcinomas, and lymph node metastases from 40 patients. Epithelial normal cells were always negative for clusterin expression and only 19% of the benign lesions presented positive staining. In contrast to the benign lesions, however, the frequency of clusterin positive samples increased in atypical hyperplasias (47%, P = 0.08), intraductal carcinomas (49%, P = 0.01) and invasive carcinomas (53%, P < 0.001). Positive staining presented a cytoplasmic pattern, except in 3 cases of invasive carcinomas which had nuclear staining. Clusterin mRNA by in situ hybridization confirmed the specific cellular pattern of clusterin expression by immunohistochemistry. Clusterin expression was associated with large tumor size (P = 0.04), estrogen and progesterone receptor negative status (P = 0.02 and P = 0.001, respectively) and with the progression from primary carcinoma to metastatic carcinoma in lymph nodes (80% metastatic nodes had positive expression) (P = 0.004). Ten of 15 (67%) primary carcinomas without clusterin expression became positive in lymph node metastases, while most (22 of 25, 88%) of the clusterin-positive primary carcinomas were also immunoreactive in metastases. In survival analysis, clusterin expression did not represent a prognostic indicator by uni- or multivariate analysis. The increased clusterin expression in breast carcinomas tended to correlate inversely with the apoptotic index (P = 0.09) which indicates that clusterin gene expression is not a prerequisite to cellular death by apoptosis. From these results, we suggest that clusterin may have a role in tumorigenesis and progression of human breast carcinomas.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10934144      PMCID: PMC1850123          DOI: 10.1016/S0002-9440(10)64552-X

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  24 in total

Review 1.  Active cell death in hormone-dependent tissues.

Authors:  M P Tenniswood; R S Guenette; J Lakins; M Mooibroek; P Wong; J E Welsh
Journal:  Cancer Metastasis Rev       Date:  1992-09       Impact factor: 9.264

2.  Expression of a novel gene encoding a 51.5 kD precursor protein is induced by different retroviral oncogenes in quail neuroretinal cells.

Authors:  D Michel; G Gillet; M Volovitch; B Pessac; G Calothy; G Brun
Journal:  Oncogene Res       Date:  1989

3.  A serum protein SP40,40 modulates the formation of membrane attack complex of complement on erythrocytes.

Authors:  N H Choi; T Mazda; M Tomita
Journal:  Mol Immunol       Date:  1989-09       Impact factor: 4.407

Review 4.  Clusterin: the intriguing guises of a widely expressed glycoprotein.

Authors:  D E Jenne; J Tschopp
Journal:  Trends Biochem Sci       Date:  1992-04       Impact factor: 13.807

5.  Ram rete testis fluid contains a protein (clusterin) which influences cell-cell interactions in vitro.

Authors:  I B Fritz; K Burdzy; B Sétchell; O Blaschuk
Journal:  Biol Reprod       Date:  1983-06       Impact factor: 4.285

6.  SP-40,40, a protein involved in the control of the complement pathway, possesses a unique array of disulphide bridges.

Authors:  L Kirszbaum; S E Bozas; I D Walker
Journal:  FEBS Lett       Date:  1992-02-03       Impact factor: 4.124

7.  Clusterin has chaperone-like activity similar to that of small heat shock proteins.

Authors:  D T Humphreys; J A Carver; S B Easterbrook-Smith; M R Wilson
Journal:  J Biol Chem       Date:  1999-03-12       Impact factor: 5.157

8.  Programmed cell death during regression of the MCF-7 human breast cancer following estrogen ablation.

Authors:  N Kyprianou; H F English; N E Davidson; J T Isaacs
Journal:  Cancer Res       Date:  1991-01-01       Impact factor: 12.701

9.  SP-40,40, a newly identified normal human serum protein found in the SC5b-9 complex of complement and in the immune deposits in glomerulonephritis.

Authors:  B F Murphy; L Kirszbaum; I D Walker; A J d'Apice
Journal:  J Clin Invest       Date:  1988-06       Impact factor: 14.808

10.  Molecular cloning and characterization of the novel, human complement-associated protein, SP-40,40: a link between the complement and reproductive systems.

Authors:  L Kirszbaum; J A Sharpe; B Murphy; A J d'Apice; B Classon; P Hudson; I D Walker
Journal:  EMBO J       Date:  1989-03       Impact factor: 11.598

View more
  61 in total

1.  Proteomic profiling of cerebrospinal fluid identifies prostaglandin D2 synthase as a putative biomarker for pediatric medulloblastoma: A pediatric brain tumor consortium study.

Authors:  Meena U Rajagopal; Yetrib Hathout; Tobey J MacDonald; Mark W Kieran; Sri Gururangan; Susan M Blaney; Peter Phillips; Roger Packer; Heather Gordish-Dressman; Brian R Rood
Journal:  Proteomics       Date:  2011-01-27       Impact factor: 3.984

Review 2.  Targeting anti-apoptotic genes upregulated by androgen withdrawal using antisense oligonucleotides to enhance androgen- and chemo-sensitivity in prostate cancer.

Authors:  Martin E Gleave; Toby Zellweger; Kim Chi; Hideaki Miyake; Satoshi Kiyama; Laura July; Simon Leung
Journal:  Invest New Drugs       Date:  2002-05       Impact factor: 3.850

Review 3.  Androgens and prostate cancer.

Authors:  Alan I So; Antonio Hurtado-Coll; Martin E Gleave
Journal:  World J Urol       Date:  2003-10-29       Impact factor: 4.226

4.  CRM1 protein-mediated regulation of nuclear clusterin (nCLU), an ionizing radiation-stimulated, Bax-dependent pro-death factor.

Authors:  Konstantin S Leskov; Shinako Araki; John-Paul Lavik; Jose A Gomez; Vivian Gama; Efstathios S Gonos; Ioannis P Trougakos; Shigemi Matsuyama; David A Boothman
Journal:  J Biol Chem       Date:  2011-09-27       Impact factor: 5.157

5.  Induction of clusterin by AKT--role in cytoprotection against docetaxel in prostate tumor cells.

Authors:  Bin Zhong; David A Sallman; Danielle L Gilvary; Daniele Pernazza; Eva Sahakian; Dillon Fritz; Jin Q Cheng; Ioannis Trougakos; Sheng Wei; Julie Y Djeu
Journal:  Mol Cancer Ther       Date:  2010-05-25       Impact factor: 6.261

6.  The tumor suppressor von Hippel-Lindau gene product and metastasis: new thoughts on an old molecule.

Authors:  Debabrata Mukhopadhyay
Journal:  Am J Pathol       Date:  2006-02       Impact factor: 4.307

7.  Screening and cloning for proteins transactivated by the PS1TP5 protein of hepatitis B virus: a suppression subtractive hybridization study.

Authors:  Jian-Kang Zhang; Long-Feng Zhao; Jun Cheng; Jiang Guo; Dan-Qiong Wang; Yuan Hong; Yu Mao
Journal:  World J Gastroenterol       Date:  2007-03-14       Impact factor: 5.742

Review 8.  Hepatitis D and hepatocellular carcinoma.

Authors:  Zaigham Abbas; Minaam Abbas; Sarim Abbas; Lubna Shazi
Journal:  World J Hepatol       Date:  2015-04-18

9.  Advances and challenges in basic and translational research on clusterin.

Authors:  Ioannis P Trougakos; Julie Y Djeu; Efstathios S Gonos; David A Boothman
Journal:  Cancer Res       Date:  2009-01-15       Impact factor: 12.701

10.  Clusterin expression inversely correlates with chemosensitivity and predicts poor survival in patients with locally advanced cervical cancer treated with cisplatin-based neoadjuvant chemotherapy and radical hysterectomy.

Authors:  Hidemichi Watari; Tatsuya Kanuma; Yoko Ohta; Mohamed Kamel Hassan; Takashi Mitamura; Masayoshi Hosaka; Takashi Minegishi; Noriaki Sakuragi
Journal:  Pathol Oncol Res       Date:  2010-01-08       Impact factor: 3.201

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.